Total Payments
$11,950
2024 Payments
$1,974
Companies
41
Transactions
570
Medicare Patients
1,220
Medicare Billing
$85,897
Payment Breakdown by Category
Food & Beverage$11,950 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,950 | 570 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,985 | 84 | $0 (2024) |
| Galderma Laboratories, L.P. | $1,631 | 58 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $996.95 | 51 | $0 (2024) |
| Janssen Biotech, Inc. | $860.06 | 55 | $0 (2024) |
| Merz North America, Inc. | $585.70 | 11 | $0 (2023) |
| LEO Pharma Inc. | $498.28 | 22 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $462.21 | 20 | $0 (2024) |
| UCB, Inc. | $437.76 | 17 | $0 (2024) |
| GENZYME CORPORATION | $419.55 | 16 | $0 (2024) |
| Mayne Pharma Inc. | $417.71 | 37 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,974 | 86 | ABBVIE INC. ($590.81) |
| 2023 | $1,433 | 72 | ABBVIE INC. ($607.48) |
| 2022 | $1,991 | 95 | Merz North America, Inc. ($402.11) |
| 2021 | $694.08 | 40 | Janssen Biotech, Inc. ($126.31) |
| 2020 | $264.31 | 13 | VYNE Pharmaceuticals Inc. ($64.30) |
| 2019 | $2,117 | 90 | Galderma Laboratories, L.P. ($559.68) |
| 2018 | $1,617 | 91 | Galderma Laboratories, L.P. ($308.38) |
| 2017 | $1,859 | 83 | Galderma Laboratories, L.P. ($328.79) |
All Payment Transactions
570 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: FACIAL AESTHETICS | ||||||
| 12/14/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $23.61 | General |
| Category: Dermatology | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $15.94 | General |
| Category: Immunology | ||||||
| 11/22/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $32.99 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/20/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | Cabtreo (Drug) | Food and Beverage | In-kind items and services | $24.67 | General |
| Category: Dermatology | ||||||
| 11/15/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Winlevi (Drug) | Food and Beverage | In-kind items and services | $21.63 | General |
| Category: Dermatology | ||||||
| 11/07/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.85 | General |
| Category: Immunology | ||||||
| 11/06/2024 | Galderma Laboratories, L.P. | DYSPORT (Biological) | Food and Beverage | In-kind items and services | $13.54 | General |
| 11/05/2024 | Biofrontera Inc. | AMELUZ (Drug), BF-RhodoLED, XEPI | Food and Beverage | Cash or cash equivalent | $21.36 | General |
| Category: DERMATOLOGY | ||||||
| 10/30/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/29/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $13.43 | General |
| Category: Immunology | ||||||
| 10/24/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $38.38 | General |
| Category: Immunology | ||||||
| 10/18/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: Dermatology | ||||||
| 10/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $7.48 | General |
| Category: Immunology | ||||||
| 10/15/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $10.71 | General |
| Category: Immunology | ||||||
| 10/09/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $26.89 | General |
| Category: Inflammation | ||||||
| 10/09/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $19.94 | General |
| 10/04/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | Cabtreo (Drug) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: Dermatology | ||||||
| 09/13/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $95.28 | General |
| Category: FACIAL AESTHETICS | ||||||
| 09/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $33.61 | General |
| Category: Immunology | ||||||
| 09/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $11.69 | General |
| Category: Immunology | ||||||
| 09/03/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $28.94 | General |
| Category: Dermatology | ||||||
| 08/15/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $29.96 | General |
| Category: Inflammation | ||||||
| 08/13/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | Cabtreo (Drug) | Food and Beverage | In-kind items and services | $22.90 | General |
| Category: Dermatology | ||||||
| 08/08/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $8.26 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 313 | 528 | $65,030 | $20,907 |
| 2022 | 8 | 443 | 708 | $93,538 | $31,295 |
| 2021 | 7 | 257 | 434 | $57,063 | $19,137 |
| 2020 | 9 | 207 | 341 | $41,047 | $14,557 |
Total Patients
1,220
Total Services
2,011
Medicare Billing
$85,897
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 95 | 126 | $23,175 | $7,903 | 34.1% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 46 | 54 | $11,507 | $3,627 | 31.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 58 | 74 | $10,329 | $2,682 | 26.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 26 | 28 | $6,671 | $2,243 | 33.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 14 | 16 | $4,161 | $1,397 | 33.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 21 | 21 | $4,791 | $1,351 | 28.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 40 | 193 | $2,711 | $1,042 | 38.5% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 13 | 16 | $1,686 | $662.22 | 39.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 105 | 144 | $25,943 | $9,397 | 36.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 62 | 74 | $15,317 | $4,887 | 31.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 64 | 64 | $14,259 | $4,396 | 30.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 45 | 51 | $11,679 | $4,138 | 35.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 80 | 97 | $13,091 | $3,454 | 26.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 21 | 28 | $7,081 | $2,665 | 37.6% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 22 | 30 | $3,120 | $1,199 | 38.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 44 | 220 | $3,047 | $1,159 | 38.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 72 | 111 | $20,120 | $6,751 | 33.6% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 43 | 51 | $10,849 | $3,732 | 34.4% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 27 | 31 | $7,145 | $2,491 | 34.9% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 32 | 32 | $7,168 | $2,437 | 34.0% |
| 17000 | Destruction of skin growth | Office | 2021 | 46 | 59 | $7,873 | $2,155 | 27.4% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2021 | 11 | 20 | $2,183 | $887.01 | 40.6% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 26 | 130 | $1,725 | $684.25 | 39.7% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2020 | 37 | 44 | $8,725 | $3,059 | 35.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 27 | 34 | $7,320 | $2,843 | 38.8% |
About Dr. Kellie Reed, M.D
Dr. Kellie Reed, M.D is a Dermatology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/08/2012. The National Provider Identifier (NPI) number assigned to this provider is 1285993535.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kellie Reed, M.D has received a total of $11,950 in payments from pharmaceutical and medical device companies, with $1,974 received in 2024. These payments were reported across 570 transactions from 41 companies. The most common payment nature is "Food and Beverage" ($11,950).
As a Medicare-enrolled provider, Reed has provided services to 1,220 Medicare beneficiaries, totaling 2,011 services with total Medicare billing of $85,897. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Austin, TX
- Active Since 05/08/2012
- Last Updated 11/20/2019
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1285993535
Products in Payments
- COSENTYX (Biological) $769.48
- TREMFYA (Drug) $608.18
- Humira (Biological) $432.52
- DORYX (Drug) $417.71
- DUPIXENT (Biological) $413.38
- EUCRISA (Drug) $403.15
- EPIDUO FORTE (Drug) $381.11
- RINVOQ (Biological) $337.05
- TALTZ (Drug) $291.37
- SOOLANTRA (Drug) $280.69
- Cimzia (Drug) $263.74
- ENSTILAR (Drug) $261.08
- BOTOX (Biological) $244.42
- OPZELURA (Drug) $212.60
- COSENTYX (Drug) $203.06
- Otezla (Drug) $188.13
- REMICADE (Biological) $187.43
- DUPIXENT DUPILUMAB INJECTION (Biological) $175.49
- Bimzelx (Biological) $174.02
- STELARA (Biological) $144.92
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Austin
Dr. Edward Lain, M.d, M.D
Dermatology — Payments: $2.3M
Dermatology $2.3M
Daniel Carrasco, Md, MD
Dermatology — Payments: $1.2M
Dermatology $1.2M
Dale Schaefer, Md, MD
Dermatology — Payments: $1.2M
Dermatology $1.2M
Janet Dubois, M.d, M.D
Dermatology — Payments: $1.1M
Dermatology $1.1M
Ms. Heidi Prather, M.d, M.D
Dermatology — Payments: $530,857
Dermatology $530,857
Daniel Friedmann, M.d, M.D
Dermatology — Payments: $231,608
Dermatology $231,608